Literature DB >> 10081086

Recent advances in identifying and validating drug targets in trypanosomes and leishmanias.

M P Barrett1, J C Mottram, G H Coombs.   

Abstract

The unique aspects of the biochemistry of trypanosomatids make rational drug design an attractive approach, but targets must be selected carefully. Genetic manipulation provides a valuable means of mimicking loss of function attributable to therapeutic intervention, but caution must be exercised when interpreting such data with respect to target validation.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10081086     DOI： 10.1016/s0966-842x(98)01433-4

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN： 0966-842X            Impact factor:   17.079


  27 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  Structural analysis of trypanosomal sirtuin: an insight for selective drug design.

Authors:  Simranjeet Kaur; Amol V Shivange; Nilanjan Roy
Journal:  Mol Divers       Date:  2009-04-29       Impact factor: 2.943

3.  Leishmania mexicana mutants lacking glycosylphosphatidylinositol (GPI):protein transamidase provide insights into the biosynthesis and functions of GPI-anchored proteins.

Authors:  J D Hilley; J L Zawadzki; M J McConville; G H Coombs; J C Mottram
Journal:  Mol Biol Cell       Date:  2000-04       Impact factor: 4.138

4.  Oral azithromycin versus its combination with miltefosine for the treatment of experimental Old World cutaneous leishmaniasis.

Authors:  Eglal I Amer; Maha M Eissa; Shereen F Mossallam
Journal:  J Parasit Dis       Date:  2014-08-31

5.  Targeting the Pentose Phosphate Pathway: Characterization of a New 6PGL Inhibitor.

Authors:  Anh Tuan Tran; Aude Sadet; Paolo Calligari; Philippe Lopes; Jamal Ouazzani; Matthieu Sollogoub; Emeric Miclet; Daniel Abergel
Journal:  Biophys J       Date:  2018-11-06       Impact factor: 4.033

6.  Activity of the novel immunomodulatory compound tucaresol against experimental visceral leishmaniasis.

Authors:  A C Smith; V Yardley; J Rhodes; S L Croft
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

7.  The co-chaperone SGT of Leishmania donovani is essential for the parasite's viability.

Authors:  Gabi Ommen; Mareike Chrobak; Joachim Clos
Journal:  Cell Stress Chaperones       Date:  2009-12-02       Impact factor: 3.667

8.  New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugs.

Authors:  Ranjan Behera; Sarah M Thomas; Kojo Mensa-Wilmot
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

9.  Methylene tetrahydrofolate dehydrogenase/cyclohydrolase and the synthesis of 10-CHO-THF are essential in Leishmania major.

Authors:  Silvane M F Murta; Tim J Vickers; David A Scott; Stephen M Beverley
Journal:  Mol Microbiol       Date:  2009-01-16       Impact factor: 3.501

10.  Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: chemical library screen and antileishmanial activity.

Authors:  Karen M Grant; Morag H Dunion; Vanessa Yardley; Alexios-Leandros Skaltsounis; Doris Marko; Gerhard Eisenbrand; Simon L Croft; Laurent Meijer; Jeremy C Mottram
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.